Mechanisms of Resistance to Targeted Therapies for Relapsed or Refractory Acute Myeloid Leukemia.

Acute myeloid leukemia (AML) is an aggressive disease of clonal hematopoiesis with a high rate of relapse and refractory disease despite intensive therapy. Traditionally, relapsed or refractory AML has increased therapeutic resistance and poor long-term survival. In recent years, advancements in the mechanistic understanding of leukemogenesis has allowed for the development of targeted therapies. These therapies offer novel alternatives to intensive chemotherapy and have prolonged survival in relapsed or refractory AML. Unfortunately, a significant portion of patients do not respond to these therapies and relapse occurs in most patients who initially responded. This review will focus on the mechanisms of resistance to targeted therapies in relapsed or refractory AML.

• Publication year

  2022

• Venue

  Experimental Hematology

• Publication date

  2022-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.exphem.2022.04.001PMID 35417742PMCID PMC10116852
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Inhibition of BCL2A1 by STAT5 inactivation overcomes resistance to targeted therapies of FLT3-ITD/D835 mutant AML

  2022cited by this paper
• A review of FDA-approved acute myeloid leukemia therapies beyond ‘7 + 3’

  2021cited by this paper
• The Ups and Downs of STAT Inhibition in Acute Myeloid Leukemia

  2021cited by this paper
• Recurrent Mutations in Cyclin D3 Confer Clinical Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia

  2021cited by this paper
• IDH Inhibitors in AML—Promise and Pitfalls

  2021cited by this paper
• Escape From Treatment; the Different Faces of Leukemic Stem Cells and Therapy Resistance in Acute Myeloid Leukemia

  2021cited by this paper
• Targeting MCL-1 in cancer: current status and perspectives

  2021cited by this paper
• Assessing acquired resistance to IDH1 inhibitor therapy by full-exon IDH1 sequencing and structural modeling

  2021cited by this paper
• Mitochondrial metabolism supports resistance to IDH mutant inhibitors in acute myeloid leukemia

  2021cited by this paper
• Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML.

  2021cited by this paper
• Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin.

  2021cited by this paper
• Mutant SETBP1 enhances NRAS-driven MAPK pathway activation to promote aggressive leukemia

  2021cited by this paper
• Chemotherapy induces senescence-like resilient cells capable of initiating AML recurrence.

  2021cited by this paper
• Oncogenic N-Ras Mitigates Oxidative Stress–Induced Apoptosis of Hematopoietic Stem Cells

  2021cited by this paper
• Nicotinamide Metabolism Mediates Resistance to Venetoclax in Relapsed Acute Myeloid Leukemia Stem Cells.

  2020cited by this paper
• Venetoclax plus LDAC for patients with untreated AML ineligible for intensive chemotherapy: phase 3 randomized placebo-controlled trial.

  2020cited by this paper
• Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia.

  2020cited by this paper
• Molecular Mechanisms of Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia: Ongoing Challenges and Future Treatments

  2020cited by this paper
• Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics

  2020cited by this paper
• Gilteritinib is a clinically active FLT3 inhibitor with broad activity against FLT3 kinase domain mutations.

  2020cited by this paper
• Fatty acid metabolism underlies venetoclax resistance in acute myeloid leukemia stem cells

  2020cited by this paper
• Venetoclax combination therapy in relapsed/refractory acute myeloid leukemia: A single institution experience.

  2020cited by this paper
• Cytogenetics and mutations could predict outcome in relapsed and refractory acute myeloid leukemia patients receiving BCL-2 inhibitor venetoclax

  2020cited by this paper
• Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML.

  2020cited by this paper
• Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia

  2020cited by this paper
• Reduced Mitochondrial Apoptotic Priming Drives Resistance to BH3 Mimetics in Acute Myeloid Leukemia.

  2020cited by this paper
• Pan-RAF Inhibition Shows Anti-Leukemic Activity in RAS-Mutant Acute Myeloid Leukemia Cells and Potentiates the Effect of Sorafenib in Cells with FLT3 Mutation

  2020cited by this paper
• Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 inhibitors.

  2020cited by this paper
• B-cell lymphoma-2 inhibition and resistance in acute myeloid leukemia

  2020cited by this paper
• 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.

  2020cited by this paper
• Emergence of BCR–ABL1 Fusion in AML Post–FLT3 Inhibitor-Based Therapy: A Potentially Targetable Mechanism of Resistance – A Case Series

  2020cited by this paper
• Single cell mutation analysis of clonal evolution in myeloid malignancies

  2020cited by this paper
• Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia

  2020cited by this paper
• Pan-RAF inhibition induces apoptosis in acute myeloid leukemia cells and synergizes with BCL2 inhibition

  2020cited by this paper
• Treatment of Relapsed Acute Myeloid Leukemia

  2020cited by this paper
• Targeting GLUT1 in acute myeloid leukemia to overcome cytarabine resistance

  2020cited by this paper
• How I Treat Relapsed or Refractory AML.

  2020cited by this paper
• Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens.

  2020cited by this paper
• Dysregulated haematopoietic stem cell behaviour in myeloid leukaemogenesis

  2020cited by this paper
• Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML.

  2020cited by this paper
• Targeting FLT3 mutations in AML: review of current knowledge and evidence

  2019cited by this paper
• RAS mutations in acute myeloid leukaemia patients: A review and meta-analysis.

  2019cited by this paper
• Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib.

  2019cited by this paper
• Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms

  2019cited by this paper
• Phase II Trial of MEK Inhibitor Binimetinib (MEK162) in RAS‐mutant Acute Myeloid Leukemia

  2019cited by this paper
• Hematopoietic cytokines mediate resistance to targeted therapy in FLT3-ITD acute myeloid leukemia.

  2019cited by this paper
• Targeting Mitochondrial Structure Sensitizes Acute Myeloid Leukemia to Venetoclax Treatment.

  2019cited by this paper
• The TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML Cells.

  2019cited by this paper
• Clonal selection with Ras pathway activation mediates secondary clinical resistance to selective FLT3 inhibition in acute myeloid leukemia.

  2019cited by this paper
• Gilteritinib induces differentiation in relapsed and refractory FLT3-mutated acute myeloid leukemia.

  2019cited by this paper
• Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial.

  2019cited by this paper
• Association of leukemia genetics with response to venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia

  2019cited by this paper
• Exploiting metabolic vulnerabilities for personalized therapy in acute myeloid leukemia

  2019cited by this paper
• Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML.

  2019cited by this paper
• Inhibition of mitochondrial translation overcomes venetoclax resistance in AML through activation of the integrated stress response

  2019cited by this paper
• Cooperation of Dnmt3a R878H with Nras G12D promotes leukemogenesis in knock-in mice: a pilot study

  2019cited by this paper
• The growing landscape of FLT3 inhibition in AML.

  2019cited by this paper
• Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia

  2018cited by this paper
• Pharmacologic inhibition of STAT5 in acute myeloid leukemia

  2018cited by this paper
• Single cell analysis of clonal architecture in acute myeloid leukaemia

  2018cited by this paper
• Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia

  2018cited by this paper
• Downregulating Notch counteracts KrasG12D-induced ERK activation and oxidative phosphorylation in myeloproliferative neoplasm

  2018cited by this paper
• Durable Remissions with Ivosidenib in IDH1‐Mutated Relapsed or Refractory AML

  2018cited by this paper
• Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib

  2018cited by this paper
• Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations

  2018cited by this paper
• Oncogenic N-Ras and Tet2 haploinsufficiency collaborate to dysregulate hematopoietic stem and progenitor cells.

  2018cited by this paper
• Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem Cells.

  2018cited by this paper
• Clinical experience with the BCL2‐inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies

  2018cited by this paper
• Cooperative Epigenetic Remodeling by TET2 Loss and NRAS Mutation Drives Myeloid Transformation and MEK Inhibitor Sensitivity.

  2018cited by this paper
• Assessing copy number abnormalities and copy-neutral loss-of-heterozygosity across the genome as best practice in diagnostic evaluation of acute myeloid leukemia: An evidence-based review from the cancer genomics consortium (CGC) myeloid neoplasms working group.

  2018cited by this paper
• Tracing the origins of relapse in acute myeloid leukaemia to stem cells

  2017cited by this paper
• FLT3 Inhibitors in Acute Myeloid Leukemia: Current Status and Future Directions

  2017cited by this paper
• p53-/- synergizes with enhanced NrasG12D signaling to transform megakaryocyte-erythroid progenitors in acute myeloid leukemia.

  2017cited by this paper
• A Genome-Wide CRISPR Screen Identifies Genes Critical for Resistance to FLT3 Inhibitor AC220.

  2017cited by this paper
• KRAS Allelic Imbalance Enhances Fitness and Modulates MAP Kinase Dependence in Cancer.

  2017cited by this paper
• Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia.

  2017cited by this paper
• Gene Essentiality Profiling Reveals Gene Networks and Synthetic Lethal Interactions with Oncogenic Ras.

  2017cited by this paper
• Heterogeneous resistance to quizartinib in acute myeloid leukemia revealed by single-cell analysis.

  2017cited by this paper
• Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response.

  2017cited by this paper
• ITD mutation in FLT3 tyrosine kinase promotes Warburg effect and renders therapeutic sensitivity to glycolytic inhibition

  2017cited by this paper
• Molecular and genetic alterations associated with therapy resistance and relapse of acute myeloid leukemia

  2017cited by this paper
• Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia.

  2016cited by this paper
• FGF2 from Marrow Microenvironment Promotes Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia.

  2016cited by this paper
• Metabolic alterations and drug sensitivity of tyrosine kinase inhibitor resistant leukemia cells with a FLT3/ITD mutation.

  2016cited by this paper
• Pim kinases modulate resistance to FLT3 tyrosine kinase inhibitors in FLT3-ITD acute myeloid leukemia

  2015cited by this paper
• How I treat refractory and early relapsed acute myeloid leukemia.

  2015cited by this paper
• Receptor tyrosine kinase Axl is required for resistance of leukemic cells to FLT3-targeted therapy in acute myeloid leukemia

  2015cited by this paper
• Decitabine and Sorafenib Therapy in FLT-3 ITD-Mutant Acute Myeloid Leukemia.

  2015cited by this paper
• FLT3 D835 Mutations Confer Differential Resistance to Type II FLT3 Inhibitors

  2015cited by this paper
• RAS signaling promotes resistance to JAK inhibitors by suppressing BAD-mediated apoptosis

  2014cited by this paper
• A distinct glucose metabolism signature of acute myeloid leukemia with prognostic value.

  2014cited by this paper
• Hematopoiesis and RAS-driven myeloid leukemia differentially require PI3K isoform p110α.

  2014cited by this paper
• SYK is a critical regulator of FLT3 in acute myeloid leukemia.

  2014cited by this paper
• Bone marrow stroma‐mediated resistance to FLT3 inhibitors in FLT3‐ITD AML is mediated by persistent activation of extracellular regulated kinase

  2014cited by this paper
• Single cell analysis exposes intratumor heterogeneity and suggests that FLT3-ITD is a late event in leukemogenesis.

  2014cited by this paper
• Internal Tandem Duplication Mutations in FLT3 Gene Augment Chemotaxis to Cxcl12 Protein by Blocking the Down-regulation of the Rho-associated Kinase via the Cxcl12/Cxcr4 Signaling Axis*

  2014cited by this paper
• Nras(G12D/+) promotes leukemogenesis by aberrantly regulating hematopoietic stem cell functions.

  2013cited by this paper
• BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells.

  2013cited by this paper
• Oncogenic Nras has bimodal effects on stem cells that sustainably increase competitiveness

  2013cited by this paper
• Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation.

  2013cited by this paper

• GATA2 links stemness to chemotherapy resistance in acute myeloid leukemia.

  2025cites this paper
• Inhibition of autophagy enhances the sensitivity of ciclopirox olamine in human chronic myelogenous leukemia K562 cells

  2025cites this paper
• Therapeutic application of allogeneic hematopoietic stem cells in childhood acute myeloid leukemia

  2025cites this paper
• Leukemia Cutis in Relapsed Acute Myeloid Leukemia: A Call for Distinct Classification

  2024cites this paper
• Enhancing Therapeutic Efficacy of FLT3 Inhibitors with Combination Therapy for Treatment of Acute Myeloid Leukemia

  2024cites this paper
• Quizartinib: a new hope in acute myeloid leukemia, an applied comprehensive review.

  2024cites this paper
• The landscape of novel strategies for acute myeloid leukemia treatment: Therapeutic trends, challenges, and future directions.

  2023cites this paper
• Emergence of BCR-ABL1 (p190) in Acute Myeloid Leukemia Post-Gilteritinib Therapy

  2023cites this paper
• Recent advance in phytonanomedicine and mineral nanomedicine delivery system of the treatment for acute myeloid leukemia

  2023cites this paper
• Exploring the Molecular Landscape of Myelofibrosis, with a Focus on Ras and Mitogen-Activated Protein (MAP) Kinase Signaling

  2023cites this paper
• Mitochondrial regulation of GPX4 inhibition–mediated ferroptosis in acute myeloid leukemia

  2023cites this paper
• Novel pyrrolidine-aminophenyl-1,4-naphthoquinones: structure-related mechanisms of leukemia cell death

  2022cites this paper